Join
Live feed
·
PRReleasevia Quantisnow
Zynerba Pharmaceuticals Inc. logo

Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome

ByQuantisnow·Wall Street's wire, on your screen.
ZYNE· Zynerba Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ZYNE (Zynerba Pharmaceuticals Inc.) and more on Quantisnow.